Psoriasis as an independent risk factor for development of coronary artery disease;Psoriasis als unabhängiger Risikofaktor für die Entwicklung einer koronaren Herzkrankheit

Deutsche Medizinische Wochenschrift

Volumn 135, Issue 36, 2010, Pages 1749-1754

  Papo, D ^a   Hein, R ^a   Ring, J ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

coronary artery disease; inflammation; myocardial infarction; Psoriasis; risk factors

Indexed keywords

C REACTIVE PROTEIN; CYCLOSPORIN A; GAMMA INTERFERON; INSULIN RECEPTOR; INTERLEUKIN 1; INTERLEUKIN 2; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; NITRIC OXIDE SYNTHASE; PROTEIN TYROSINE KINASE; RETINOID; ROSUVASTATIN; TUMOR NECROSIS FACTOR ALPHA;

BODY MASS; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERLIPOPROTEINEMIA; IMMUNOPATHOGENESIS; INSULIN RESISTANCE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOME ASSESSMENT; PSORIASIS; PSORIASIS SEVERITY INDEX; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; TH1 CELL; TH17 CELL;

CORONARY ARTERY DISEASE; HUMANS; PSORIASIS; RISK FACTORS;

EID: 77956297881     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0030-1263310     Document Type: Review

References (50)

1. Aicher A, Heeschen C, Mohaupt M et al. Nicotine strongly activates dentritic cell-mediated adaptive immunitiy: potential role for progression of atherosclerotic lesions. Circulation 2003 107 604-611
2. Alberti K G., Zimmet P Z. Definition, diagnosis of diabetes mellitus and its complications, I: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998 15 539-553
3. Alexandroff A B., Pariah Camp R DR, Lang C C., Struthers A D., Armstrong D J. More than skin deep: atherosclerosis as a systemic manifesation of psoriasis. Br J Dermatol 2009 161 1-7
4. Boehncke W H., Buerger C, Boehncke S. Komorbiditäten bei Psoriasis vulgaris. Hautarzt 2009 60 116-121
5. Boehncke S, Thaci D, Beschmann H et al. Psoriasis patients show signs of insulin resistance. Br J Dermatol 2007 157 1249-1251
6. Choi K H., Hernan M A., Seeger J D. et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002 359 1173-1177
7. Christophers E. Psoriasis epidemiology and clinical spectrum. Clin Exp Dermatol 2001 26 314-320
8. Schwandt P, Richter W O. Adipostas. In: Classen M, Diehl V, Kochsiek K, Innere Medizin. 4. Auflage. Urban und Schwarzenberg 1998 787
9. Dixon W G., Watson K D., Lunt M et al. Reduction oin the incidence of myokardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007 56 2905-2912
10. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Panel III). JAMA 1998 285 2486-2497
11. Friedewald V E., Cather C C., Gelfand J M. et al. AJC Editors Consensus: Psoriasis and Coronary Artery Disease. Am J Cardiol 2008 102 1631-1643
12. Fritsch P. Erythematosquamöse Dermatosen. In: Fritsch P, Dermatologie Venerologie. 2. Auflage. Berlin Heidelberg New York Springer-Verlag 2004 360-374
13. Gelfand J M., Weinstein R, Porter S B. et al. Prevalence and treatment of psoriasis in the United Kingdom: a population based study. Arch Dermatol 2005 141 11537-11541
14. Gelfand J M., Neimann A L., Shin D B. et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006 296 1735-1741
15. Gelfand J M., Troxel A B., Lewis J D. et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 2007 143 1493-1499
16. Gisondi P, Tessari G, Conti A, Piaserico S, Peserico A, Gianetti A, Girolomoni G. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-besed case-control study. Br J Dermatol 2007 157 68-73
17. Hansson G K. Inflammation, Atherosclerosis and Coronary Artery Disease. N Engl J Med 2005 352 1685-1695
18. Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 1995 32 982-986
19. Herron M D., Hinckley M, Hofman M S. et al. Impact of obesity and smoking om psoriasis presentation and management. Arch Dermatol 2005 141 1527-1534
20. Jacobsson L T., Turesson C, Gülfe A et al. Treatment with tunor necrosis factor blockers is associated with a lower incidence of first cardiovascular events im patients with rheumatoid arthritis. J Rheumatol 2005 32 1213-1218
21. Katz H I., Waalen J, Leach E E. Acitretin in psoriasis: an overview of adverse effects. J Am Acad Dermatol 1999 41 S7-S12
22. Kremers H M., Crowson C S., Nicola P J., Ballmann K V. et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2005 52 402-411
23. Kremers H M., Mc Evoy M T., Dann F et al. Heart disease in psoriasis. J Am Acad Dermatol 2007 57 347-354
24. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a mewly recognized type of immunomodulator. Nat Med 2000 6 1399-1402
25. Lakka H M., Laaksonen D E., Lakka T A. et al. The metabolic syndrome and cardiovascular disease mortality in middle-aged man. JAMA 2002 288 2709-2716
26. Lindegard B. Diseases associated withpsoriasis in a generl population of 159.200 middle-aged, urban, native Swedes. Dermatologica 1986 172 298-304
27. Ludwig R J., Herzog C, Rostock A, Ochsendorf F R., Zollner T M., Thaci D, Vogl T J., Boehncke W H. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol 2006 156 271-276
28. Mallbirs L, Akre O, Granath F et al. Increased risk for cardiovaskular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004 19 225-230
29. Mallbris L, Granath F, Hamsten A, Stahle M. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol 2006 54 614-621
30. Mann D L., McMurray J JV, Packer M, Swedberg K et al. Targeted anticytokine therapy in patients with chronic heart failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004 109 1594-1602
31. McCarey D W., McInnes I B., Mashok R et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised Placebo-controlled trial. Lancet 2004 363 2015-2021
32. McDonald C J., Calabresi P. Complication of Psoriasis. JAMA 1973 224 629
33. McDonald C J., Calabresi P. Occlusive vascular disease in psoriatic patients. N Engl J Med 1973 288 912
34. Mehta N N., Azfar R S., Shin D B., Neimann A L., Troxel A B., Gelfand J M. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J 2010 31 1000-1006
35. Naldi L. Cigarette smoking and psoriasis. Clin Dermatol 1998 16 571-574
36. Naldi L, Chatenoud L, Linder D et al. Cigarette smoking, body mass index and stressfull life events as risk factors for psoriasis: results from an Italian case control study. J Invest Dermatol 2005 125 61-67
37. Neimann A L., Shin D B., Xingmei W, Margolis D J., Troxel A B., Gelfland J M. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006 55 829-835
38. Neimann A L., Porter S B., Gelfand J M. Epidemiology of psoriasis. Expert Rev Dermatol 2006 1 63-75
39. Prodanovich S, Ma F, Taylor J R. et al. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 2005 52 262-267
40. Ridker P M. Testing the inflammatory hypothesis of atherothrombosis: scientific rationle for the cardiovascular inflammation reduction trial (CIRT). J Throm Haemost 2009 7 Suppl. 1 332-339
41. Ridker P M., Danielson E, Fonesca F HA et al. Reduction in C-reactive protein and LDL cholesterol and cardiovacular event rates after initiation of rosuvastatin: a prospective study oft he JUPITER trial. Lancet 2009 373 1175-1182
42. Rocha-Pereira P, Santos-Silva A, Rebelo I et al. Dislipidemia and oxidative stress in mild and severe psoriasis as a risk for cardiovascular disease. Clin Chim Acta 2001 303 33-39
43. Schoen T, Boehncke H W. Psoriasis. N Engl J Med 2005 352 1899-1912
44. Setty A R., Curhan G, Choi H K. Obesity, waist circumference, weight change and the risk of psoriasis in women: Nurses Health Study II. Arch Intern Med 2007 167 1670-1675
45. Sommer D M., Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006 298 321-328
46. Sopori M. Effects of cigarette smoke on the immune system. Nat Rev Immunol 2002 2 372-377
47. Stern R S., Fitzgerald E, Ellis C N. et al. The saftey of etretinate as long-term therapy for psoriasis: results of the etretinate follow-up study. J Am Acad Dermatol 1995 33 44-52
48. Taler S j, Textor C S., Canzanello V J., Schwartz L. Cyclosporin-induced hypertension: incidence, pathogenesis and management. Drug Saf 1999 20 437-449
49. Wakkee M, Thio H B., Prens E P., Sijbrands E JG, Neumann H AM. Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients. Atheroslerosis 2007 190 1-9
50. Xiao J, Chen L H., TU Y T., Deng X H., Tao J. Prevalence of myocardial infarction in patients with psoriasis in central China. JEADV 2009 23 1311-1315